Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.
We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD [(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate]. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly normalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.
D002118:Calcium / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate; D012189:Retrospective Studies; D012507:Sarcoidosis / Q000150:complications* / Q000378:metabolism
D004164:Diphosphonates; D000077268:Pamidronate; D002118:Calcium